Navigation Links
European Commission's Joint Research Centre's annual report 2010
Date:5/6/2011

This report provides an overview of the activities, accomplishments and resources related to the JRC's work carried out during 2010 and includes figures on staff, budget and publications.

In her foreword, Commissioner Mire Geoghegan-Quinn, in charge of research, innovation and science, highlights the need for policy making based on the best possible advice and affirms that "the JRC has built an excellent reputation as a world-class provider of scientific and technical support to European policy makers and legislators". The Commissioner refers as well to the role of the JRC as a "trusted and truly independent voice advising us on what is on the horizon in order to take timely policy decisions".

JRC Director-General, Dominique Ristori, emphasizes JRC efforts to support the Europe 2020 policy priorities addressing major challenges such as health, safety and security.

Examples of JRC's results throughout the year are described, such as the European-wide electricity grid model, contributions to the car emissions regulations, the crisis response work to Haiti and the methods to measure mycotoxins in infant food.

Many other highlights of JRC's work in different areas, such as energy (including nuclear), safety of food and consumer products, open and competitive economy or sustainable management of natural resources can also be found in the report.

In addition, an overview is given of the JRC mission and its implementation, the scientific activities and relations with the outside world. It covers as well the JRC input to the various stages of the policy cycle: from anticipation and formulation to policy adoption, implementation and evaluation.


'/>"/>

Contact: Elena Gonzalez Verdesoto
elena.gonzalez-verdesoto@ec.europa.eu
322-299-9862
European Commission Joint Research Centre
Source:Eurekalert

Page: 1

Related biology technology :

1. Cyberonics Announces First Implant of AspireSR™ Seizure Response Product in European Trial
2. Saladax Biomedical, Inc. Announces European Commercialization Team
3. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
4. European Commission Approves DuPont Tender Offer to Acquire Danisco
5. Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
6. BioStorage Technologies Appoints New Director of Business Development for European Operations
7. Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
8. ACT Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for hESC-Derived RPE Cells for Treatment of Stargardts Disease
9. Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market
10. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
11. European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
Breaking Biology News(10 mins):